文献速递肝病

GLE/PIB在3至<12岁慢性丙肝儿童中的药代动力学、安全性与疗效

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.
PubMed 文献 · Hepatology · 2021-01-01

DORA第二部分是一项2/3期非随机开放标签研究,评估GLE/PIB儿童制剂在3至<12岁慢性HCV感染儿童中的药代动力学、疗效与安全性。80例入组并给药患儿中96%(77/80)达到SVR12,药代暴露与成人相当,多数不良事件为轻度,无药物相关严重不良事件。

要点

  • 80例3至<12岁慢性HCV儿童接受基于体重的GLE/PIB治疗,96%(77/80)达到SVR12。
  • 最终有效剂量为GLE 250mg+PIB 100mg(≥30至<45kg)、200mg+80mg(≥20至<30kg)、150mg+60mg(12至<20kg)。
  • 药代暴露与成人相当,多数不良事件为轻度,无药物相关严重不良事件。

核心结论

  • GLE/PIB儿童制剂在3至<12岁慢性HCV感染儿童中高度有效且耐受良好。

研究设计与样本

  • DORA第二部分为2/3期、非随机、开放标签研究,评估GLE/PIB儿童制剂在3至<12岁慢性HCV感染儿童中的药代动力学、疗效与安全性。
  • 患儿按年龄分为队列2(9至<12岁)、队列3(6至<9岁)、队列4(3至<6岁),接受基于体重的GLE/PIB治疗8、12或16周。

主要发现

  • 80例入组并给药患儿中96%(77/80)达到SVR12。
  • 1例使用初始剂量比例的患儿在治疗后第4周前复发;使用最终剂量比例(GLE 50mg/PIB 20mg)的患儿无病毒学失败。
  • 2例无应答者提前终止研究。
  • 多数不良事件为轻度,无药物相关严重不良事件。
  • 药代动力学暴露与成人相当。

关键数值与推荐

  • 最终确定有效的儿童剂量为:体重≥30至<45kg者GLE 250mg+PIB 100mg;≥20至<30kg者GLE 200mg+PIB 80mg;12至<20kg者GLE 150mg+PIB 60mg。
  • 主要终点为治疗后第12周持续病毒学应答(SVR12)和稳态暴露;次要终点包括持续性病毒血症、复发和再感染率。

临床怎么用

  • 对于3至<12岁慢性HCV感染儿童,可按体重选择上述GLE/PIB剂量方案治疗8、12或16周。
  • 治疗期间需监测病毒学应答及不良事件,多数不良事件为轻度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Glecaprevir/pibrentasvir (GLE/PIB) has shown high efficacy and safety in chronic HCV-infected adults and adolescents; data in children were limited. DORA part 2 is a phase 2/3, nonrandomized, open-label study evaluating the pharmacokinetics, efficacy, and safety of a pediatric formulation of GLE and PIB in children ages 3 to < 12 years. APPROACH AND RESULTS: Children with chronic HCV infection, genotype 1-6, with or without compensated cirrhosis, were divided into three cohorts by age-cohort 2 (9 to < 12 years), cohort 3 (6 to < 9 years), and cohort 4 (3 to < 6 years)-and given weight-based doses of GLE and PIB for 8, 12, or 16 weeks. Primary endpoints were sustained virologic response at posttreatment week 12 (SVR12) and steady-state exposure; secondary endpoints were rates of persistent viremia, relapse, and reinfection. Safety and laboratory abnormalities were assessed. Final pediatric dosages determined to be efficacious were 250 mg GLE + 100 mg PIB (in children weighing ≥ 30 to < 45 kg), 200 mg GLE + 80 mg PIB (≥ 20 to < 30 kg), and 150 mg GLE + 60 mg PIB (12 to < 20 kg). Of 80 participants enrolled and dosed, 96% (77/80) achieved SVR12. One participant, on the initial dose ratio, relapsed by posttreatment week 4; no participants had virologic failures on the final dose ratio of GLE 50 mg/PIB 20 mg. Two nonresponders prematurely discontinued the study. Most adverse events (AEs) were mild; no drug-related serious AEs occurred. Pharmacokinetic exposures were comparable to those of adults. CONCLUSIONS: A pediatric formulation of GLE/PIB was highly efficacious and well tolerated in chronic HCV-infected children 3 to < 12 years old.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Jonas MM, Rhee S, Kelly DA, et al. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021. PMID: 33811356. doi:10.1002/hep.31841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。